Application of blood derived growth factors in treatment of gum disease
- Conditions
- Health Condition 1: K056- Periodontal disease, unspecified
- Registration Number
- CTRI/2021/12/038681
- Lead Sponsor
- Dr Anupama Tadepalli
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
1.Subject with moderate periodontal disease with the case definition, Stage III periodontitis, according to EFP-AAP periodontal disease classification 2017. i.e., Moderate periodontal destruction is defined as sites having � 5mm probing pocket depth with attachment loss
2.Moderate periodontal destruction at least, in 2 interproximal sites in each quadrant.
3.Minimum presence of 4 permanent teeth per quadrant (excluding 3rd molars)
1.Sites with pseudo pockets / advanced periodontal destruction with mobility and Grade IV furcation involvement
2.Periodontal therapy within last 6 months
3.Previous history of intake of antibiotics over last 6 months
4.Systemic condition / disease, having influence on course and treatment outcomes of periodontal disease.
5.Screening for the infectious disease will be done and the subjects with infectious diseases will be excluded.
6.Individuals with known platelet disorders
7.Smokers.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the changes in Clinical attachment level (CAL) before and after therapy within and between the groups.Timepoint: Baseline, 3 months, 6 months
- Secondary Outcome Measures
Name Time Method To assess the changes in Probing pocket depth (PPD) before and after therapyTimepoint: Baseline, 3 months, 6 months